Can one target T-cell ALL?
Best Pract Res Clin Haematol
; 31(4): 361-366, 2018 12.
Article
em En
| MEDLINE
| ID: mdl-30466748
ABSTRACT
Progress in our understanding of the central genes, pathways, and mechanisms in the pathobiology of T-cell acute lymphoblastic leukemia (T-ALL) has identified key drivers of the disease, opening new opportunities for therapy. Drugs targeting highly prevalent genetic alterations in NOTCH1 and CDKN2A are being explored, and multiple other targets with readily available therapeutic agents, and immunotherapies are being investigated. The molecular basis of T-ALL is reviewed here and potential targets and therapeutic targets discussed.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Sistemas de Liberação de Medicamentos
/
Inibidor p16 de Quinase Dependente de Ciclina
/
Receptor Notch1
/
Leucemia-Linfoma Linfoblástico de Células T Precursoras
/
Imunoterapia
/
Antineoplásicos
Limite:
Humans
Idioma:
En
Revista:
Best Pract Res Clin Haematol
Assunto da revista:
HEMATOLOGIA
Ano de publicação:
2018
Tipo de documento:
Article